Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
2Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
TriSalus Life Sciences, Inc. (TLSI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
8Total relationships
2Distinct source URLs
6High confidence
0.833Average confidence
2026-07-01Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
TriSalus Life Sciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
DYNAVAX-TECHNOLOGIES
DYNAVAX-TECHNOLOGIES
92%
We purchased all of the intellectual property and trial drug substance for nelitolimod from Dynavax Technologies ("Dynavax") in 2020.
LSCM
LSCM
90%
The Company has agreed not to sell or otherwise dispose of any of the Company's securities for a period ending 90 days after the date of the Underwriting Agreement without first obtaining the written…
TriSalus Life Sciences, Inc. Customers
Ticker
Name
Confidence
Evidence
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
. Our clinical trials are still in early stages, and there is no certainty that we will generate favorable data or that, upon review, the FDA will approve nelitolimod for sale. Recent Developments No…
LAKE-STREET-CAPITAL-MARKETS-LLC
LAKE-STREET-CAPITAL-MARKETS-LLC
62%
ns with research and other key personnel as to the progress of studies or other services being performed. Nonrefundable advance payments for goods and services are deferred and recognized as expense …
TriSalus Life Sciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TLSI-DEBT-13015
Warrants outstanding: 11.5
90%
xbrl warrant detail from xbrl 2024-12-31.
TLSI-DEBT-13016
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
TLSI-DEBT
Debt stack $34.5M
90%
Market cache reports total debt of $34.5M.
TriSalus Life Sciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for TriSalus Life Sciences, Inc..
TriSalus Life Sciences, Inc. Ownership
Holder
Name
Confidence
Evidence
TLSI-OWNER-FIRST-LIGHT-ASSET-MANAGEMENT-LLC
First Light Asset Management, LLC
90%
13F overlay lists First Light Asset Management, LLC as top holder; 85 tracked holders.
TriSalus Life Sciences, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
